Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells

@article{Hui2004AgentsWS,
  title={Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells},
  author={Aimin Hui and Wei Zhang and Wei Hua Chen and Dan Xi and Benjamin Purow and Glenn C Friedman and Howard A. Fine},
  journal={Cancer Research},
  year={2004},
  volume={64},
  pages={9115 - 9123}
}
  • A. Hui, Wei Zhang, +4 authors H. Fine
  • Published 2004
  • Biology, Medicine
  • Cancer Research
Tamoxifen, a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER)-expressing breast cancer. It has previously been shown that high-dose tamoxifen has cytotoxic activity against glioma cells, but whether this effect is drug specific or represents a general property of SERMs is unknown. In this study, we demonstrate that tamoxifen and CC-8490, a novel benzopyranone with SERM activity, induce glioma cell apoptosis in a dose… Expand
Involvement of estrogen receptor β5 in the progression of glioma
TLDR
The findings suggest hypoxia induced ERβ5 expression in glioma as a self-protective mechanism against tumor proliferation and that ER β5 might serve as a therapeutic target for the treatment ofglioma. Expand
Raloxifene-Induced Myeloma Cell Apoptosis: A Study of Nuclear Factor-κB Inhibition and Gene Expression Signature
TLDR
Raloxifene induces myeloma cell cycle arrest and apoptosis partly through NF-κB-dependent mechanisms, offering the framework for future studies of selective estrogen receptor modulators therapy in multiple myelomas. Expand
Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells
TLDR
Induction of a rapid mitochondrial cell death program in breast cancer cells at pharmacological concentrations of Tam is demonstrated, which are achievable in tumor tissue of Tam-treated breast cancer patients. Expand
Estrogen receptor α enhances the transcriptional activity of ETS-1 and promotes the proliferation, migration and invasion of neuroblastoma cell in a ligand dependent manner
TLDR
It is demonstrated that ERα may be a novel ETS-1 co-activator and thus a potential therapeutic target in human neuroblastoma treatment, and this effect was related to ligand-mediated activation of ERα. Expand
The role of ERα36 in cell type-specific functions of estrogen and cancer development.
TLDR
It seems that ERα36 is highly involved in cell type-specific functions of estrogen through its MAPK/ERK signaling, which is dependent on ER α36 expression levels, ligand concentrations and disease stage, and these factors influence the ERK kinetic and determine the ultimate mitogenic or antimitogenic signaling of estrogen, leading to cell survival or cell death. Expand
Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells
TLDR
Results indicate that ERRalpha and ERRgamma are differentially expressed in these tumor cell lines and likely contribute to agonist-dependent ERR transcriptional activity. Expand
Estradiol induces JNK-dependent apoptosis in glioblastoma cells.
TLDR
The blockade of the c-jun NH(2)-terminal kinase (JNK) signaling pathway prevented these effects of estradiol, indicating the critical role of the JNK/c-jun signaling cascade in glioblastoma cell growth inhibition and cell death in response to high concentrations of est radiol. Expand
Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals
TLDR
C-Src, ERK, and AKT played a protective role during TAM-induced apoptosis, and that c-Cbl sensitized MCF-7 cells to TAM by modulating the expression of c-SRC, and Tamoxifen-induced ERK andAKT activity. Expand
ER-α36, a novel variant of ERα, is involved in the regulation of Tamoxifen-sensitivity of glioblastoma cells
TLDR
It is suggested that resistance to TAM involves ER-α36, which probably acts as a negative regulator of TAM-induced inhibition of glioblastoma cell growth, and a further study is underway to reveal more about the specific molecular mechanisms associated with ER- α36-mediated TAM resistance. Expand
Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature
TLDR
Recent accumulated data suggest that both raloxifene and tamoxifen could be useful in chemoprevention and the attempt to overcome chemo-drug resistance using high-dose SERMs would be one approach to developing such a strategy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells.
TLDR
The existence of calcium signaling in breast cancer and glioma cells is demonstrated and tamoxifen is identified as a potential modulator of tumor-associated calcium signaling. Expand
Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro.
TLDR
It is suggested that diethylstilbestrol and tamoxifen may kill human breast cancer cells by an independent mechanism of action and that the cytocidal activity of diethYLstil bestrol and the proliferative effect of 17 beta-estradiol appear to be independent of estrogen receptor status. Expand
Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro.
TLDR
The mechanism of growth inhibition by tamoxifen in these gliomas did not involve an estrogen receptor-mediated process but may instead result from its inhibition of PKC, which is a known PKC inhibitor. Expand
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
TLDR
Findings provide experimental evidence that ER-alpha gene silencing in prostate cancer cells, and perhaps also in normal PrECs, are caused by DNA hypermethylation. Expand
Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.
TLDR
Clinical trials of tamoxifen in ovarian cancer, hepatocellular carcinoma, desmoid tumors, malignant glioma, pancreatic carcinomas, melanoma, and renal cell carcinoma are reviewed. Expand
The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients.
TLDR
A clinical trial of orally administered tamoxifen, 20 mg twice daily, to patients with recurrent, progressive malignant gliomas who were not candidates for other "failed" protocols, and may show some efficacy against glial neoplasms is concluded. Expand
Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
TLDR
It is demonstrated that the activation of NF-κB in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and the inhibition of NF -κB is established as a new approach to adjuvant therapy in cancer treatment. Expand
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
TLDR
It is suggested that anti-Fas MoAb-induced apoptosis in MM cells is associated with activation of SAPK, and that IL-6 may both inhibit apoptosis and modulate SAPK activity. Expand
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
TLDR
It is demonstrated that protein-tyrosine phosphatase SHP2 mediates the anti-apoptotic effect of IL-6 and is suggested as a novel therapeutic target in MM. Expand
Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?
  • E. Gelmann
  • Biology, Medicine
  • Journal of the National Cancer Institute
  • 1996
TLDR
The current meta-analysis of HAI treatment for liver metastases from colorectal cancer provides useful and insightful results regarding this treatment regimen and highlights the need to evaluate trade-offs in clinical research. Expand
...
1
2
3
4
5
...